Genentech, Biogen ask FDA to broaden Rituxan use

Genentech and partner Biogen Idec are asking the FDA to allow their cancer drug Rituxan to be used in combination with chemotherapy for people with chronic lymphocytic leukemia. Report

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Intent-driven audiences are inspired to make health-improving changes after a positive online experience. Find out what they’re driven to do.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.